Conversely, another study reported a superior OS in BRAF Non-V600E subgroup compared to the BRAF V600E subgroup of NSCLC patients (5.0 vs. 14.0 m, P = 0.017) [28]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.